Kaken Pharmaceutical Co., Ltd. (4521.T) JPX

3,790.00

+5(+0.13%)

Updated at June 03 03:23PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Hiroyuki Horiuchi	Chairman, President & Representative Director	103M	1962
Tomohiro Takaya	General Manager of Legal Affairs & Intellectual Property Department	0	N/A
Hideki Kawabata	Head of Clinical Development Department	0	N/A
Keizo Kimura	Corporate Officer, Chief Officer of Production Division & Chief of Shizuoka Factory	0	N/A
Masashi Suzudo	MD, Director of the Corporate Planning & Coordination Department and Director	0	1962
Gaku Kametsu	General Manager of Corporate Communications Department	0	N/A
Masaru Ogawa	Chief Officer of Regulatory Affairs Division & GM of Regulatory Affairs Department	0	N/A
Tatsuhiro Harada	Deputy Chief Officer of R&D Division & Chief of Drug Research Center	0	N/A
Mitsuru Watanuki	Chief Officer of R&D Division and Director	0	1964
Tomoyuki Koseki	Chief Officer of Marketing & Sales Division	0	N/A

Name

Title

Pay

Year Born

Hiroyuki Horiuchi

Chairman, President & Representative Director

103M

1962

Tomohiro Takaya

General Manager of Legal Affairs & Intellectual Property Department

N/A

Hideki Kawabata

Head of Clinical Development Department

N/A

Keizo Kimura

Corporate Officer, Chief Officer of Production Division & Chief of Shizuoka Factory

N/A

Masashi Suzudo

MD, Director of the Corporate Planning & Coordination Department and Director

1962

Gaku Kametsu

General Manager of Corporate Communications Department

N/A

Masaru Ogawa

Chief Officer of Regulatory Affairs Division & GM of Regulatory Affairs Department

N/A

Tatsuhiro Harada

Deputy Chief Officer of R&D Division & Chief of Drug Research Center

N/A

Mitsuru Watanuki

Chief Officer of R&D Division and Director

1964

Tomoyuki Koseki

Chief Officer of Marketing & Sales Division

N/A

Description

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.